Citation Impact
65 standout
Citing Papers
Targeting the Warburg Effect in Cancer: Where Do We Stand?
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Xiaoming Hou being referenced
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC).
2022
LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma
2018
Author Peers
| Author | Molecular Biology | Oncology | PRM | Cancer Research | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Xiaoming Hou | 368 | 168 | 121 | 204 | 56 | 712 | |
| Yogeshwar Bachhav | 59 | 19 | 8 | 4 | 14 | 727 | |
| Christian Reller | 13 | 641 | |||||
| Hongwen Dai | 12 | 2 | 2 | 13 | 479 | ||
| Elizabeth Plunk | 52 | 6 | 2 | 25 | 7 | 293 | |
| V L Gilbart | 13 | 1 | 10 | 322 |
All Works
Login with ORCID to disown or claim papers
Loading papers...